Skip to search boxSkip to navigationSkip to main content

Endothelial AMPKα1/PRKAA1 exacerbates inflammation in HFD-fed mice

  • Qiuhua Yang
    ,
  • Qian Ma
    ,
  • Jiean Xu
    ,
  • Zhiping Liu
    ,
  • Xiaoxiao Mao
    ,
  • Yaqi Zhou
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Background and Purpose: Excess nutrient-induced endothelial cell inflammation is a hallmark of high fat diet (HFD)-induced metabolic syndrome. Pharmacological activation of the protein kinase AMP-activated α1 (PRKAA1) also known as AMPKα1, shows its beneficial effects in many studies of cardiometabolic disorders. However, AMPKα1, as a major cellular sensor of energy and nutrients in endothelial cells, has not been studied for its physiological role in excess nutrient-induced endothelial cell (EC) inflammation. Experimental Approach: Wild-type and EC-specific Prkaa1 knockout mice were fed with an HFD. Body weight, fat mass composition, glucose, and lipid levels were monitored regularly. Insulin sensitivity was analysed systemically and in major metabolic organs/tissues. Inflammation status in metabolic organs/tissues were examined with quantitative RT-PCR and flow cytometry. Additionally, metabolic status, inflammation severity, and signalling in cultured ECs were assayed with multiple approaches at the molecular level. Key Results: EC Prkaa1 deficiency unexpectedly alleviated HFD-induced metabolic syndromes including decreased body weight and fat mass, enhanced glucose clearance and insulin sensitivity, and relieved adipose inflammation and hepatic steatosis. Mechanistically, PRKAA1 knockdown in cultured ECs reduced endothelial glycolysis and fatty acid oxidation, decreased levels of acetyl-CoA and suppressed transcription of inflammatory molecules mediated by ATP citrate lyase and histone acetyltransferase p300. Conclusions and Implications: This unexpected pro-inflammatory effect of endothelial AMPKα1/PRKAA1 in a metabolic context provides additional insight in AMPKα1/PRKAA1 activities. An in-depth study and thoughtful consideration should be applied when AMPKα1/PRKAA1 is used as a therapeutic target in the treatment of metabolic syndrome.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1661-1678 (18 pages)

Journal (Volume, Issue Number)

British Journal of Pharmacology (Volume 179, Issue 8)

Publication milestones

  • Accepted/In press - 2021
  • Published - 04/2022

Publication status

Published - 04/2022

ISSN

0007-1188

Publication IDs

  • Scopus: 85121719614
  • PubMed: 34796475
  • ORCID: /0000-0002-0305-4122/work/124760265

Publication metrics

Metrics

Fractional count
4
Fractional count
0.31
Fractional count
9
Fractional count
0.69
Fractional count
4
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
10
Citation count
11

Funding Details

This work was supported by the National Institutes of Health (R01HL134934 and R01EY030500) and American Heart Association (19TPA34910043).
FundersFunding numbers
NIH
R01EY030500
NHLBI
R01HL134934
AHA
19TPA34910043